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Abstract
Introduction: Both neurosarcoidosis and central nervous system lymphoma can be very difficult to diagnose. We
describe the case of a patient in whom neurosarcoidosis was strongly suspected, but who was eventually found to
have lymphoma. We believe the case to be of interest and practical value to neurologists, oncologists and
internists with an interest in inflammatory diseases.
Case presentation: A diagnosis of neurosarcoidosis was considered in a 49-year-old Caucasian man on the basis
of the following symptoms and indications: a cough, bilateral hilar lymphadenopathy confirmed by thoracic
computed tomography, the development of an S1 radiculopathy, cerebrospinal fluid abnormalities (raised protein
level), bilateral lung hilar and lachrymal gland uptake on a gallium scan, and erythema nodosum confirmed with
skin biopsy. These were followed by the development of multiple cranial neuropathies, including seventh nerve
palsy. Exhaustive further investigations yielded no evidence for an alternative diagnosis. Treatments with steroids,
cyclophosphamide, intravenous immunoglobulin and finally infliximab were of no benefit. He eventually developed
cutaneous nodules, a biopsy of which revealed lymphoma that proved resistant to therapy.
Conclusion: Constant diagnostic vigilance is required in disorders such as neurosarcoidosis.
Introduction
Systemic inflammatory, autoimmune, infectious or neo-
plastic disorders frequently involve the central nervous
system (CNS). Establishing a diagnosis can be particu-
larly difficult when neurological symptoms are the pre-
senting feature. Biological markers or diagnostic
evidence of other organ involvement can be absent, and
the perceived hazards, combined with the potential for
eliciting only non-diagnostic information, often mitigate
against cerebral biopsy.
We present the case of a patient that illustrates such
difficulties and we discuss the implications of using
aggressive immunosuppressive therapy in patients with
suspected inflammatory disease.
Case presentation
A 49-year-old Caucasian man developed a cough in
early 2004. A chest X-ray revealed bilateral hilar lym-
phadenopathy, confirmed by thoracic computed tomo-
graphy (CT) scan. He had no other symptoms. A
diagnosis of sarcoidosis was considered, but his symp-
toms were thought insufficient to warrant treatment.
In July 2004, he developed numbness and pain behind
the right knee which gradually spread to the lower back,
right buttock and posterior thigh. Upon examination he
had reduced sensation over the lateral border of the
right foot, an absent right ankle tendon reflex and a
positive Lasègue’s sign at 70°. He also had a dusky dis-
colouration of the skin of the right foot.
He was admitted to our hospital in September 2004
because of progressive worsening of the symptoms.
Lumbrosacral spinal magnetic resonance imaging (MRI)
showed an increased heterogeneous signal within the S1
nerve root and of the nerve root ganglion on T2 images,
thought to be due to oedema, with right piriformis wast-
ing. His cerebrospinal fluid (CSF) contained no white
cells, 0.52 g/l protein and 0.36 g/l glucose. Nerve con-
duction studies and an electromyogram (EMG) revealed
abnormalities in the S1 segment, consistent with an S1
radiculopathy. Serum angiotensin converting enzyme
(sACE) was persistently normal but an isotope-labelled
gallium scan showed increased bilateral lung hilar and
lachrymal gland uptake. He developed skin nodules on
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erythema nodosum. The diagnosis of sarcoidosis was
considered overwhelmingly likely, and in the absence of
compression, the involvement of the S1 root was
thought most likely due to neurosarcoidosis. He started
treatment with prednisone 30 mg/day but his pain per-
sisted; intravenous steroids and then local steroid nerve
root injection was tried with temporary benefit. In April
2005, he started methotrexate (up to 12.5 mg per week)
because of persistent pain and the need to lower his
steroid dose because of his elevated glucose levels.
In November 2005, he developed left peri-orbital and
hemicranial headache, followed by diplopia on left gaze.
He was found to have a partial left sixth nerve palsy and
was re-admitted. MRI showed thickening and gadoli-
nium enhancement in the left cavernous sinus with no
parenchymal change. Repeat gallium scanning showed
normal lung hilar and lachrymal gland uptake. Serum
rheumatoid factor, plasma viscosity, C-reactive protein,
urea and electrolytes, liver function, clotting, auto-
immune profile, protein electrophoresis, acetylcholine
receptor antibodies, anti-neuronal antibodies, anti-thyr-
oid antibodies, creatine kinase and ACE were all normal.
He was treated with a three-day course of intravenous
methylprednisone and experienced significant
improvement.
The following month, he developed headache and
further diplopia and he was found to have a painful
pupil-sparing left third nerve palsy. His CSF was again
entirely normal, including negative oligoclonal band
assay. Brain and orbit MRI scanning were normal. EMG
and nerve conduction studies suggested improvement of
S1 radiculopathy. He also complained of left facial pain
with tearing of the left eye. There was a patchy decrease
in sensation on the left side of the face and scalp. Cor-
neal reflex was diminished. Blink reflex and facial nerve
conduction studies showed an afferent defect on the left
suggesting a left trigeminal ophthalmic division neuro-
pathy. His prednisone was increased to 60 mg/day, and
cyclophosphamide was started instead of methotrexate.
However, after reducing his steroids to 40 mg/day,
severe facial pain recurred.
In March 2006, he developed numbness and tingling
on the left side of his face, and was found to have a left
maxillary ophthalmic division Vth neuropathy. A month
later he developed a lower motor neuron left seventh
nerve palsy and numbness in the right shoulder and in
the left thorax. His CSF was again normal and/or nega-
tive including cytological study, acid-fast bacilli staining,
and fungal and Mycobacterium tuberculosis cultures and
sACE was also still normal. His blood count showed
mild lymphopenia and macrocytosis. Lactate dehydro-
genase was normal. Borrelia, syphilis, cytomegalovirus,
HIV and human T-lymphotropic virus Type 1 serology
were negative. An ophthalmological examination was
normal with no signs of granulomata.
At this stage, new neurological symptoms developed
while the patient was on treatment with steroids and
cyclophosphamide. Because no diagnosis emerged other
than sarcoidosis, alternative immunosuppressive therapy
was administered. Intravenous immunoglobulins, how-
ever, had no impact. Infliximab was added in June 2006.
Despite this, the patient’s right shoulder became weak,
his headache persisted and he also developed unsteadi-
ness of gait and significant weight loss. He now had
bilateral seventh nerve palsies with weakness of the left
palate, right serratus anterior, right triceps, left triceps
and left finger abductors. All the upper limb deep ten-
don jerks were absent. A left vocal cord palsy was
noted. EMG and nerve conduction studies showed
abnormalities compatible with a pre-ganglionic lesion at
C5 and C6 level (right), but no generalised neuropathy.
Repeat brain MRI scanning showed enhancement of the
fifth, sixth, seventh and eighth cranial nerves (Figure 1).
Spine MRI scanning was normal. MRI scanning of the
upper brachial plexus was normal. A CT scan of the
pelvis and abdomen were normal. A whole body fluoro-
deoxyglucose-positron emission tomography (FDG-PET)
scan was normal. Urine thallium screening and lead
level were negative. Upper gastrointestinal endoscopy
was normal.
The patient then developed three subcutaneous nodules,
one in the left outer inferior breast quadrant, without lym-
phadenopathy. Biopsy of the nodules showed lymphoma-
tous change, and the final diagnosis was diffuse large B-
cell lymphoma involving cranial and peripheral nerves
(neurolymphomatosis). Bone marrow was normal.
He was transferred to the Oncology department and
treated with chemotherapy including methotrexate.
After chemotherapy he received total body irradiation
and a bone marrow stem cell transplant. There was no
significant improvement in his neurological condition.
Discussion
S a r c o i d o s i si sa ni n f l a m m a t o r ys y s t e m i cd i s o r d e ro f
unknown cause. Neurosarcoidosis is a serious complica-
tion found in 5 to 15% of patients with sarcoidosis and
often has a poor prognosis; treatment is recommended
in the early period of disease. It most commonly causes
cranial neuropathies, but any part of nervous system can
be involved [1]. Peripheral nerve involvement is less
common and usually occurs in 15 to 18% of patients [2].
When neurological problems develop in patients with
biopsy-proven systemic sarcoidosis, the diagnosis is
usually straightforward. However, without biopsy evi-
dence of sarcoidosis in other sites, neurological sarcoi-
dosis may be difficult to diagnose and other disorders
difficult to exclude, particularly infection and neoplasia.
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starting treatment cannot be exaggerated [3], and our
case helps illustrate this. Tissue-based proof of sarcoido-
sis was, despite our best efforts, never acquired. Had the
patient undergone a transbronchial biopsy at the onset
of his illness (when he had bilateral hilar adenopathy), it
is highly likely that a definitive diagnosis - probably of
lymphoma - would have emerged, but at this stage he
had no other symptoms. Our experience here helps
emphasize the importance of tissue proof in simple
cases - before and/or in case they become more com-
plex. In more cryptic cases - and neurosarcoidosis can
notoriously be difficult to differentiate from a wide
range of other inflammatory and non-inflammatory con-
ditions [1] - ‘blind’ biopsy of certain tissues such as con-
junctiva and muscle can occasionally also yield
diagnostic results (also reviewed in [1]).
In this patient, neurosarcoidosis was clinically an
attractive explanation for his presenting problems:
cough, hilar lymphadenopathy (confirmed by thoracic
CT), development of a S1 radiculopathy, CSF abnormal-
ities (raised protein level), bilateral lung hilar and lachry-
mal gland uptake on gallium scan, and erythema
nodosum confirmed with skin biopsy, followed by the
development of multiple cranial neuropathies, including
seventh nerve palsy.
CSF abnormalities are seen in 80% of patients with
neurosarcoidosis, but are non-specific; likewise, serum
and CSF ACE (consistently normal in this patient) are
also an insensitive test for sarcoidosis [1,4,5]. A brain
MRI may show multiple non-specific white matter
lesions, isointense on T1-weighted images, high signal
intensity in T2-weighting, and with contrast enhance-
ment of both the lesions and meninges.
The diagnosis of neurosarcoidosis requires a compati-
ble clinical, laboratory and/or radiological picture of sar-
coidosis and histological confirmation of non-caseating
granulomas [6]. In ‘probable’ neurosarcoidosis (Table 1),
as in our patient, aggressive or experimental therapy
should be commenced only with very great caution and
in particular in the case of tumour necrosis factor block-
ade, following the utmost efforts to exclude tuberculosis.
The progressive neurological deterioration of our
patient, with no opportunity for histological interroga-
tion, was thought to warrant such a therapeutic
approach. Unfortunately, this produced no beneficial
results for the patient. Erythema nodosum, of course, is
Figure 1 Brain magnetic resonance images. (a) Brain magnetic
resonance image scanning T2 weighted image showing high signal
of the fifth, sixth, seventh and eighth cranial nerves (arrow). (b)
Brain magnetic resonance image scanning T1 after gadolinium
showing enhancement of the fifth, sixth, seventh and eighth cranial
nerves (arrow).
Table 1 Diagnostic criteria for neurosarcoidosis establish
definite, probable and possible disease [6]
Definite Clinical presentation compatible with neurosarcoidosis
Exclusion of other possible causes
Positive nervous system histology
Probable Clinical presentation compatible with neurosarcoidosis
Laboratory support of CNS inflammation*
Exclusion of other possible causes
Evidence of systemic sarcoidosis**
Possible Clinical presentation compatible with neurosarcoidosis
Exclusion of other possible causes
*High concentrations of CSF protein and high numbers of cells, the presence
of oligoclonal bands, or MRI evidence compatible with neurosarcoidosis.
**Positive histology or at least two indirect indicators from gallium scan, chest
imaging, and serum angiotensin converting enzyme.
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a recognized cause.
Neurolymphomatosis represents a unique subtype of
extra-nodal lymphoma with localised invasion of cranial
or peripheral nerves, plexuses or nerve roots. In the vast
majority of reported patients, the disease is a large B-
cell non-Hodgkin’s lymphoma (NHL) [7]. Usually it
develops in patients with widespread systemic NHL, but
the nervous system may be the sole site, and patients
often present without known lymphoma [8]. Despite the
infrequent clinical presentation of neurological compli-
cations, autopsy studies indicate common involvement
of the peripheral nervous system [9]. In our patient,
serum LDH was consistently normal and CSF cytology
was always unremarkable - but in fact, only a minority
of cases has positive CSF cytology [10]. His low lympho-
cyte count may have represented a clue, but a bone
marrow biopsy (even at the time his skin nodules had
developed) was normal, as was FDG-PET scanning -
again, not unusual in some instances of lymphoma [11].
Cyclophosphamide and steroid treatment in this
patient could have suppressed his lymphoma and so
delayed its diagnosis. Paradoxically, it is not impossible
that he did have refractory sarcoidosis warranting
aggressive chemotherapy, but then developed lym-
phoma, that is, he had two diseases, but we believe this
to be unlikely and that he had lymphoma at the outset.
Cyclophosphamide may contribute to tumourigenesis;
alternatively infliximab, at least in patients with inflam-
matory bowel disease, has been implicated in the devel-
opment of lymphoma [12] - though conversely, one
epidemiologically robust study involving almost 20,000
patients with rheumatoid arthritis found that infliximab
was not associated with a greater risk of lymphoma [13].
Indeed, infliximab is even considered a potential treat-
ment in other haematological neoplastic disorders
including myelodysplastic syndromes [14].
Conclusions
Constant diagnostic vigilance and clinical surveillance is
required in disorders such as neurosarcoidosis, and the
importance of a tissue diagnosis - not obtained in this
case until very late in the course and then excluding sar-
coid - cannot be overemphasised.
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